Advertisement

BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation

BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation
From Reuters - November 13, 2017

Nov 13 (Reuters) - Zymeworks Inc

* Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics

* Says US$50 million upfront license fee paid to Zymeworks for up to six bispecific programs

* Says Zymeworks licenses azymetric and efect platforms to Janssen

Advertisement

Continue reading at Reuters »